Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic’s anemia drug found reducing blood transfusion
Chemotherapy-induced anemia (CIA) patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of
Chemotherapy-induced anemia (CIA) patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of
Of the original 20 patients enrolled at the nab-paclitaxel 100mg/m2 dose, 17 had levels of CA 19-9 that could be evaluated. CA 19-9 levels dropped more than 20%
According to PharmaTimes, the FDA has asked Pfizer to suspend the 30-second online video advertisement for Viagra (sildenafil), which appeared on CNN.com. FDA believes that Pfizer’s ad has
According to the firm’s annual drug trend report, the average copayment paid by insured patients fell down to $13.20 in 2007 from $13.45 in 2006, even though the
The company recently unveiled a cream which is formulated to provide lasting pain relief. Stopain Cream incorporates Invisicare, an extended-release polymer technology that works on contact, rapidly and
The Iota-Beactica platform couples comprehensive, site-directed fragment-based drug discovery (FBDD) libraries to state-of-the-art fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling the rapid progression
Analyses of 12-month interim antibody data in the first 125 patients randomized in the study indicate that for all patients treated with 900mg, 300mg, or 100mg of Riquent
The median overall survival rate was 27 weeks and both this efficacy and the safety profile compares favorably with current medical treatments which often include palliative best supportive
The lead compound, which is positioned for clinical trials within a year, targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate. Dale
IDX184 is a nucleotide prodrug derived from Idenix’s proprietary liver- targeting technology. Results from in vitro and in vivo preclinical studies confirm that this technology preferentially activates IDX184